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Objective: Age is an important prognostic factor for lung cancer. However, no studies have investigated the age 
difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors 
on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand. 
Materials and Methods: We extracted 22 487 new lung cancer cases aged 50–99 (median age = 71, 47.1 % fe-
males) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer 
registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, depri-
vation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we 
derived corresponding lung cancer net survival. 
Results: The age difference in net survival was particularly marked for localised and regional lung cancers, with a 
sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with 
localised cancer. However, for other stages, females had a greater difference in survival between middle-age and 
older-age than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation 
did not influence age disparities in lung cancer survival. 
Conclusion: Sex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in 
New Zealand.   
1. Introduction 
Patients aged 75 years or over have lower lung cancer survival than 
younger patients [1]. Although lung cancer survival has improved in 
recent decades, older patients have not benefitted from the improve-
ment in treatment as much as younger patients [1]. The excess mortality 
in older patients with lung cancer has been observed for up to five years 
since diagnosis [2]. 
In New Zealand, lung cancer was the third most common cancer 
diagnosis and the second cause of cancer death in adults aged 70 years 
and over in 2018 [3]. As in other countries, lung cancer five-year sur-
vival in patients under the age of 75 has recently improved in New 
Zealand (from 13.0 % (95 % confidence interval: 11.9 %–14.0 %) in 
1995–1999 to 18.8 % (17.5 %–20.2 %) in 2010–2014) [1]. However, no 
improvement was observed for patients aged 75 years or older (from 7.9 
% (6.6 %–9.4 %) in 1995–1999 to 7.4 % (6.2 %–8.8 %) in 2010–2014), 
with New Zealanders aged 75 years or older having the lowest lung 
cancer survival among seven high-income countries with a similar 
healthcare system [1]. 
Because of the higher likelihood of multiple comorbidities, poly-
pharmacy, age-related physiological changes, frailty, lower functional 
performance, limited life expectancy [4,5] and additionally the under-
representation of older patients in randomised clinical trials, lung cancer 
management in older patients is challenging [6]. As a result, older pa-
tients with lung cancer have been found to be less likely to receive 
cancer treatment than younger patients [7,8]. Also, older adults are 
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more likely to be diagnosed with lung cancer after a presentation to the 
emergency department, which in turn was associated with advanced 
cancer and poor survival prospect [9]. While these factors and other 
social factors may explain poor prognosis in older patients, a recent 
literature review reveals that a few studies only focused on the differ-
ence in lung cancer survival between older patients and younger pa-
tients and looked at a particular factor (e.g., socioeconomic deprivation) 
[10]. To tackle age disparities in lung cancer survival, the main drivers 
of these disparities should be identified. 
Using population-based cancer registry data linked to hospitalisation 
data, we describe the role of patient-related and clinical factors on the 
age pattern in lung cancer survival and excess mortality hazard by stage 
at diagnosis in New Zealand. 
2. Methods 
We included patients aged between 50 and 99 years old at diagnosis, 
diagnosed with lung cancer (ICD-10 code C34) between 1 January 2006 
and 31 July 2017 registered in the New Zealand population-based 
cancer registry (NZ-PBCR). We restricted our analyses to patients with 
a first occurrence of lung cancer. We linked these cancer cases to hos-
pitalisation data (National Minimum Dataset) for the five years before 
the cancer diagnosis, and to the outpatient dataset (National Non- 
Admitted Patient Collection) where all emergency admissions are 
recorded. We obtained the date of death for all cancer cases who died 
between 1 January 2006 and 31 December 2019 from the Ministry of 
Health. 
We categorised the extent of disease as given by NZ-PBCR into Sur-
veillance, Epidemiology and End Results (SEER) stage groups as follows: 
Localised to the organ of origin or Invasion of adjacent tissue or organ 
into SEER localised stage; Regional lymph nodes involvement into SEER 
regional stage; Distant into SEER distant stage; Not known into missing 
stage [11]. 
We used the “all-sites” weighted C3 index developed by Sarfati et al. 
to assess comorbidity among patients with cancer using administrative 
hospitalisation data [12]. We defined emergency presentation at diag-
nosis as a cancer diagnosis occurring in the 28 days following admission 
to an emergency department [13]. 
Sex and age at diagnosis were available for all lung cancer cases 
within the NZ-PBCR, originating from pathology reports and National 
Health Index database. We used the New Zealand Deprivation Index 
(NZDep) to assess the socio-economic deprivation at cancer diagnosis 
[14]. The NZDep is an ecological indicator built using the nine following 
variables from the national census: housing tenure, benefit receipt, un-
employment, income, telephone access, car access, single-parent fam-
ilies, education and household crowding. The NZdep was assigned to 
domicile code (census area) of each patient at the time of diagnosis. For 
all diagnoses occurring during the period 2006–2011, we used the 
NZDep based on information collected at the 2006 census; for all di-
agnoses occurring from 2012, we used the score based on information 
from the 2013 census. We could not map domicile code to an NZDep 
score for 77 cases; we, therefore, excluded these cases from analyses. 
Self-reported ethnicity available in the NZ-PBCR originated from the 
hospital records. Ethnicity refers to the ethnic group people identify 
with or feel they belong to, and not to race, ancestry, nationality or 
citizenship (https://www.stats.govt.nz/topics/ethnicity). Ethnicity data 
were not available for 86 cases; we, therefore, excluded these cases from 
analyses. 
3. Statistical analysis 
When studying the survival of cancer patients, it is important to 
recognize that patients might die from their disease but also from other 
causes. This becomes crucial when looking at the effect of age at diag-
nosis as older patients are subjected to a greater risk of dying from 
competing causes (cardiovascular diseases, etc.). Net survival is the 
indicator commonly used to analyse population-based cancer registry 
data when information on cause of death is either missing or deemed 
unreliable. Net survival is a particularly interesting indicator in this 
context: it represents the hypothetical survival that would be observed if 
lung cancer were the only cause of death. 
Net survival is derived from the estimation of individual excess 
mortality hazard (EMH): the overall hazard of death for cancer patients 
is assumed to be the sum of the expected (or background) hazard and the 
excess hazard due to cancer. The excess hazard embeds direct (e.g., 
multiple organ failure resulting from cancer progression) and indirect 
(e.g., treatment toxicity, pulmonary embolism) effects of cancer on 
mortality. We used lifetables of mortality in the general population to 
estimate expected mortality, defined by calendar period (2005–2007 
and 2012–2014), single year of age, sex, and ethnicity (Māori, non- 
Māori) obtained from Statistics New Zealand (http://archive.stats.govt. 
nz/browse_for_stats/health/life_expectancy/period-life-tables. 
aspx#gsc.tab=0). We built lifetables for each calendar year between 
2006 and 2013 assuming linear interpolation between the age-, sex- and 
ethnic-specific mortality rates in 2005–7 and 2012–14. We extrapolated 
the rates beyond 2014 using the same constant yearly change in mor-
tality. We fitted flexible excess hazard regression models for each stage 
at diagnosis. We censored all patients who were still alive beyond 10 
years after diagnosis. The model-building strategy is available in sup-
plemental Material. 
All predictions presented in the manuscript were made for Non- 
Māori males diagnosed in 2012, who lived in an area with third quintile 
of deprivation index, with median comorbidity score, no emergency 
admission recorded in the month prior to their cancer diagnosis, unless 
otherwise stated. 
3.1. Sensitivity analysis 
Net survival estimated in the relative survival setting relies on the 
accuracy of estimates of the expected mortality in general population. 
Indeed, it is assumed that the other-cause mortality rate for lung cancer 
patients is that same as the mortality rate of the general population. 
However, lung cancer patients are more likely to be smokers and 
therefore have a higher risk of dying from diseases other than cancer 
(such as COPD, cardiovascular diseases). As a result, the mortality 
hazard of the general population might underestimate the other-cause 
mortality rate of lung cancer patients. Studies have shown that lung 
cancer mortality hazard can be overestimated, and, consequently, lung 
cancer net survival was underestimated when not using smoking- 
specific life-tables [15,16]. 
To correct for this we amended the NZ lifetable for smoking status 
using the method described by Ellis et al. [17]. Briefly, we calculated a 
correction coefficient from the smoking prevalence obtained by sex and 
5-year age band (50–54, …., 80–85, 90+) from the 2013 New Zealand 
population census, and the hazard ratios of all-cause mortality in 
smokers compared to non-smokers with average adjustment by 5-year 
age group (50–54; …; 70–74, 75+). As smoking status at patient level 
was unknown, we assumed they were all smokers, and we used the 
corrected lifetable for smokers. We ran the stage-specific models pre-
viously obtained with the corrected expected mortality rates. 
We performed data management using Stata (version 16.0; Stata-
Corp, 2019) and statistical analyses using R statistical software (version 
3.4.0; R Development Core Team, 2017), in particular the ‘mexhaz’ 
package was used for flexible excess hazard modelling [18]. 
4. Results 
Out of 23,645 patients diagnosed with lung cancer in 2006− 17 in 
New Zealand, we included 22,487 (95.1 %) patients aged 50–99 years at 
diagnosis (median age = 71, interquartile range 64–79), 47.1 % of 
whom were females. Table 1 describes patients’ characteristics by age 
group and supplementary Table 1 by age group and stage at diagnosis. 
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Over half the patients aged 65 years or over were males. Māori 
represented one-third of lung cancer patients aged 50− 64 years, but 
only 4 % in the 85− 99 years age group. The number of cases increased 
with increasing deprivation (supplementary Table 1). Overall, 6.0 % of 
patients were diagnosed with localised cancer, 12.4 % with regional 
cancer, 44.4 % with distant cancer, and 37.1 % had a missing stage. The 
percentage of missing stage increased with age at diagnosis. Among 
patients with known stages, lung cancer was mostly diagnosed at an 
advanced stage in all age groups. The percentage of patients with at least 
one comorbidity increased with age from 66 % in the 50− 64 age group 
to around 75 % after 75 years old. Lung cancer was diagnosed following 
an emergency presentation in the previous 28 days in 40.6 % of patients, 
and this percentage was highest after the age of 85 (47.7 %), and in 
patients with distant cancer (54.0 %). 
Net survival decreased with more advanced disease (Fig. 1): 93.2 % 
(95 % confidence interval: 91.7 %–94.7 %) and 87.8 % (85.7 %–89.9 %) 
of patients with localised disease survived their cancer beyond 1 and 3 
years respectively, which was 58.1 % (56.5 %–59.7 %) and 33.1 % (31.4 
%–34.8 %) of patients with regional cancer, 14.6 % (14.0 %–15.2 %) 
and 3.9 % (3.6 %–4.3 %) of patients with distant cancer, and 40.4 % 
(39.4 %–41.4 %) and 14.0 % (13.3 %–14.7 %) of patients with missing 
stage. Regardless of stage at diagnosis, net survival decreased as age at 
diagnosis increased (Fig. 1 and supplementary Table 2). The age dif-
ference in net survival was more marked for localised and regional 
stages cancers than in other stages, and the smallest difference was 
observed at three years in patients with distant cancer. We noted a clear 
decline in survival from the age of 70 for localised and regional disease, 
but a more gradual decline from the age of 50 for advanced disease. 
The age pattern of EMH in patients with lung cancer by stage at 
diagnosis is presented in Fig. 2. The excess risk of death increased with 
more advanced disease for all ages. In patients with localised cancer, 
compared with patients aged 55 years old, those aged over 75 years old 
had higher excess mortality over the entire follow-up, while those aged 
65 years had higher excess mortality from 3 months after diagnosis. In 
patients with regional cancer, the excess mortality in the oldest patients 
was obvious over the 2.5 first years since diagnosis and was highest in 
the first 12 months. For patients with distant cancer, the highest risk of 
death was observed during the first year since diagnosis for all ages. The 
excess risk in the oldest patients was visible over the entire follow-up, 
Table 1 
Characteristics of patients with lung cancer by age at diagnosis.  
Age categories 
(years) 
50− 64 65− 74 75− 84 85− 99 Total 
Cases (%) 6062 7735 6498 2192 22487 
Deaths 5354 7036 6212 2182 20784 
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Fig. 1. Lung cancer net survival for patients aged 55, 65, 75 and 85 years old over the first three years since diagnosis (top panel), and one-and three-year lung 
cancer net survival by age at diagnosis (bottom panel) by stage at diagnosis. 
S. Pilleron et al.                                                                                                                                                                                                                                 
Lung Cancer 157 (2021) 92–99
95
but highest in the first 9 months. In patients with missing stage, the 
excess risk of deaths was highest in the first three months regardless of 
age at diagnosis. The excess mortality in older patients persisted over the 
entire follow-up. 
Female patients younger than 75–80 years old had better net survival 
than males regardless of the stage at diagnosis (Fig. 3). However, with 
Fig. 2. Excess mortality hazard for patients aged 55, 65, 75 and 85 years old (top panel), and excess mortality hazard ratio for patients aged 65, 75 and 85 years 
compared to patients aged 55 years old during the first three years since lung cancer diagnosis by stage at diagnosis (bottom panel). 
Fig. 3. One-year net survival in patients with lung cancer aged 50–99 years by age at diagnosis, stage at diagnosis and patient-related and clinical factors.  
S. Pilleron et al.                                                                                                                                                                                                                                 
Lung Cancer 157 (2021) 92–99
96
localised disease, the female advantage persisted in older ages, whereas 
the sex difference disappeared around the age of 75 in patients with 
regional cancer, around 80–85 years in patients with distant cancer and 
the difference reversed from the age of 85 in patients with a missing 
stage. Māori patients had consistently poorer net survival than non- 
Māori patients. Deprivation level was not retained in the final model in 
patients with a missing stage (supplementary Table 3). For other stages, 
net survival decreased as the deprivation level increased, but the 
magnitude of the difference was less marked as cancer was more 
advanced. The role of comorbidity in net survival varied across stages. In 
localised cancer and missing stage, one-year net survival decreased as 
comorbidity level decreased. In patients with regional cancer, patients 
without comorbidity had slightly better one-year net survival than other 
patients regardless of age at diagnosis. In patients with distant cancer, 
the difference in net survival across comorbidity levels was small and 
curves crossed at 60 and 85 years showing a slighlty better one-year net 
survival in patients with comorbidity aged between these two ages. 
Patients who were diagnosed with lung cancer following an emergency 
presentation had consistently and significantly poorer net survival than 
other patients regardless of age at diagnosis and stage at diagnosis. 
We finally tested the potential effect modification of patient-related 
and clinical factors on the age pattern of EMH (supplementary Table 3). 
No factors influenced the relationship of age on the EMH in patients with 
localised cancer. In patients with regional cancer, EMH ratio was higher 
in females at all ages, and over the entire follow-up time, but greater in 
the oldest women and the first three months since diagnosis (Fig. 4). For 
distant cancer and missing stage, EMH ratio was higher in females than 
in males from around the age of 80, and the difference in EMH ratio 
between females and males was similar over time. 
Comorbidity level interacted significantly with age at diagnosis for 
patients with distant cancer (Supplementary Table 3). However, the 
pattern of EMH ratio did not differ much across comorbidity levels 
(Fig. 5A). An emergency presentation modified the effect of age at 
diagnosis on EMH in patients with distant cancer (Fig. 5B) and those 
with a missing stage (Fig. 5C). For distant cancers, patients diagnosed 
after an emergency presentation aged 60–80 had higher EMH ratio than 
those who were not, but the difference between the two groups was 
small. A different pattern was observed for patients with a missing stage. 
Patients with an emergency presentation had similar EMH ratio than 
other patients up to the age of 75. Then, the EMH ratio increased in 
patients without emergency presentation only in the first year since 
diagnosis before being close to one three years after diagnosis. 
4.1. Sensitivity analysis 
The model for localised tumours could not be fitted when using the 
corrected mortality tables because the expected mortality rate became 
higher than the observed mortality rate, resulting in a negative excess 
hazard contrary to the assumptions underlying the model construction. 
For the other stages, the correction of expected mortality rates 
yielded higher net survival estimates in the oldest patients (supple-
mentary Table 5) in all stages while it had a small influence in estimates 
in younger patients, therefore reducing the age gap in survival. How-
ever, the correction did not influence the age pattern of survival based 
on the studied factors (Supplementary Figs. 1–5). 
5. Discussion 
We described, for the first time, the role of patient-related and 
clinical characteristics on age pattern in net survival and excess mor-
tality hazard in patients with lung cancer aged 50 or over. Among pa-
tient factors, female patients had greater age disparities in net survival 
than males. Stage at diagnosis was the main clinical factor that impacted 
age disparities, especially in the first year after cancer diagnosis, with 
bigger age disparities in non-advanced cancer. Ethnicity, deprivation 
level, comorbidity and an emergency presentation all were associated 
with net survival, but they were not drivers of age disparities in lung 
cancer survival in New Zealand. 
The observation of greater age disparities in lung cancer survival in 
females than in males is congruent with previous literature. For 
instance, in the study by Dickman et al., females aged 45–59 years old 
had better one-year relative survival than males of the same age; how-
ever, females aged 75 years or older had lower one-year relative survival 
than males [19]. Even if some evidence suggests a positive effect of sex 
Fig. 4. Excess mortality hazard ratios at 3, 6 months,1 and 3 years by age at diagnosis based on sex in patients with (A) regional lung cancer, (B) distant lung cancer, 
(C) missing stage (reference: 55 years old). 
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hormones on survival in females [20], the implication of sex hormones is 
still not clear [21] and deserves further investigation. The female sur-
vival advantage may be explained by a higher likelihood of treatment 
receipt in females than in males. A recent descriptive study in New 
Zealand showed higher rates of surgical resection and systemic anti-
cancer therapy in females than in males but these results are merely 
descriptive and may be confounded by other factors [22]. A United 
States study suggested that female patients were less likely to receive 
timely treatment [23], but the United States healthcare system is 
different from that in New Zealand; therefore, difficult to compare. 
Another hypothesis is that female patients respond better to treatment 
than males. To our knowledge, there is no study that investigated this 
question in New Zealand, but studies in other settings give favour to this 
hypothesis [24–26]. However, the female advantage would be restricted 
to adenocarcinoma and large-cell carcinoma cases [27]. Further studies 
are needed to better understand the survival advantage in females. 
Our study confirmed poorer survival in Māori patients with lung 
cancer and the negative role of deprivation level on lung cancer survival. 
However, ethnicity and deprivation level did not influence the age dif-
ference in lung cancer survival. Previous studies in the U.S and the UK 
suggested that race/ethnicity could have a role in age disparities, but 
results were inconsistent [28,29], probably because of differences be-
tween health-care systems. We are aware of one study on the role of 
socioeconomic status in age disparities in lung cancer survival, but it 
does not provide clear pattern for the role of socioeconomic level on age 
disparities in lung cancer survival [30]. Another study suggested smaller 
age disparities in deprived areas compared with affluent areas in En-
gland [31]. 
Comorbidity is highly prevalent in patients with lung cancer, espe-
cially in older patients that are also more likely to have multiple 
comorbidities than younger patients [4]. While the interaction between 
comorbidity and age at diagnosis contributed significantly to the model, 
the actual effect of comorbidity had on age disparities was limited. A 
previous study presenting lung cancer survival data by age group and 
comorbidity level suggested greater age disparities in patients without 
comorbidities than those with severe comorbidities [32]. It is possible 
that some aspects of comorbidity were not captured by the C3 Index 
used to assess comorbidity level in our study. Indeed, the C3 index was 
created using hospitalisation data, excluding comorbidities that were 
not recorded during hospitalisation events, and those that did not 
require hospitalisation [12]. However, when compared to an index 
constructed using pharmaceutical data in cancer patients in New Zea-
land (not including lung cancer), the C3 Index performed similarly [33]. 
Comorbidity alone is not enough to assess vulnerabilities in older pa-
tients with cancer, and comprehensive geriatric assessments may be 
useful in capturing a more nuanced view of health, fitness and physio-
logical aging [34]. 
As expected and consistently with previous studies [35], stage at 
diagnosis influenced age disparities in lung cancer survival. We 
observed the difference in survival between younger and older patients 
was highest in early stages of the disease, probably explained by age 
disparities in treatment receipt and outcomes. In later stage, the high 
lethality of the disease may explain the smaller difference in survival 
disparities observed between middle-aged and older patients. This 
observation with that about comorbidity above suggest that age dis-
parities in lung cancer survival increased as cancer was amenable to 
treatment. The association between disparities in survival and amena-
bility to treatment was previously described about racial disparities in 
cancer survival [36]. Stage at diagnosis guides cancer treatment strat-
egy. Surgery is recommended in fit older patients with early lung cancer 
[37]. For patients deemed unfit or unwilling to undergo surgery, 
radiotherapy is a valid option. Chemoradiation is recommended in more 
advanced cancers, even in older patients [37]. Yet, older patients are less 
likely to receive surgery, chemotherapy or radiation [7,8,38]. Some 
evidence suggested, however, that some of them, with appropriate 
stratification, may benefit from treatment [39,40]. Because of the 
under-representation of older patients in clinical trials [6], clinicians 
lack evidence about the benefit-risk balance in older patients of 
Fig. 5. Excess mortality hazard ratios at 3, 6 months,1 and 3 years by age at diagnosis based on (A) comorbidity in patients with distant lung cancer, (B) emergency 
in patients with distant lung cancer, (C) or missing stage (reference: 55 years old). 
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potential treatment strategy and may be reluctant to offer curative 
treatment to their older patients. However, accumulating evidence show 
that comprehensive geriatric assessment (CGA) helps to identify patients 
who will benefit the most from treatment [41,42]. Emergency presen-
tation, another indicator of cancer diagnosis timeliness, influenced age 
pattern in lung cancer survival in patients to a lesser extent. We are not 
aware of previous studies investigating the role of emergency presen-
tation on age disparities in lung cancer survival. Early detection of lung 
cancer is likely to improve survival prospects for all patients including 
older ones, but this is unlikely to reduce age disparities in survival if no 
improvement in treatment is made for older patients. 
Unfortunately, we were not able to investigate the role of treatment 
in this study. Because age disparities in cancer care is likely to be the 
main driver of age disparities in survival, it is more than urgent to 
improve the representation of older adults in clinical trials. Some 
ongoing clinical trials focus specifically on adults aged over 70 (e.g. 
https://clinicaltrials.gov/ct2/show/NCT03977194). Observational 
studies may be a good alternative to study the effect of treatment in age 
disparities. However, many are at high risk of bias, especially immortal 
time bias [35]. While waiting for clinical trials data, observational 
studies using appropriate methods to handle immortal time and selec-
tion biases are warranted to study the effect of treatment on age dis-
parities in lung cancer survival [43]. 
Our study has limitations. The stage at diagnosis was missing for 37 
% of patients. Stage information was obtained through NZ-PBCR. They 
collect staging information from pathology reports; therefore, staging 
information is most complete for tumours where the primary treatment 
is surgical. In cases where patients had no surgery (most patients with 
lung cancer), cancer registry coders use information available. If they 
are unable to determine stage, the stage will be missing. Patients without 
stage recorded tended to be older, have at least one comorbidity, less 
likely to be diagnosed as emergency than patients with stage informa-
tion (Supplementary Table 4). We recognize that patients without in-
formation on stage will be an heterogeneous group and further work 
would benefit from imputing stage information for these patients. 
Additionally, we acknowledge that age disparities in lung cancer 
survival may differ depending on other unstudied factors such as those 
related to the tumour (e.g. morphology grouping), the patient (e.g. 
performance status, frailty) or access to health care system, etc. How-
ever, in the present study, we restricted the number of variables inves-
tigated because of the relatively low number of cases by stage. 
Another limitation comes from the fact that many lung cancers are 
clinically diagnosed, and the NZ PBCR receives most of its information 
from laboratories. This may impact especially older patients for whom 
clinicians may be less inclined to offer diagnostic work-up. However, the 
underreporting of lung cancer cases in the NZ PBCR has been estimated 
to be around 1–4 % [44,45]. 
Finally, while we observed net survival estimates were influenced by 
the correction of the expected mortality rates, our correction was 
approximate: we obtained smoking prevalence for the year 2013 and 
this may not reflect exactly the prevalence for the other years although 
we would not expect dramatic changes year on year. In addition, we did 
not have information on smoking prevalence by ethnicity; the smoking 
status of patients was unknown. However, the lifetable’s correction only 
had a minor impact on the age-related survival pattern based on patient- 
related and clinical factors. 
International comparison of lung cancer survival has revealed great 
differences even within each stage at diagnosis [1], especially in older 
patients, suggesting difference in lung cancer management across 
countries. Further studies in other countries are then warranted to 
confirm our findings or identify other factors influencing age patterns in 
lung cancer survival. 
6. Conclusion 
The present population-based study confirms the survival advantage 
of females and the importance of stage at diagnosis in age disparities in 
lung cancer survival, that is probably explained by age difference in lung 
cancer management. In contrast, comorbidity or an emergency presen-
tation at diagnosis did not drive age disparities in lung cancer in New 
Zealand. Future studies should investigate the impact of geriatric factors 
and treatment on age difference in lung cancer survival. 
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